Home Federal Bank of Tennessee Sells 769 Shares of Pfizer Inc. (NYSE:PFE)

Home Federal Bank of Tennessee reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 2.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 26,535 shares of the biopharmaceutical company’s stock after selling 769 shares during the period. Home Federal Bank of Tennessee’s holdings in Pfizer were worth $672,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of PFE. Rialto Wealth Management LLC bought a new stake in Pfizer in the 4th quarter valued at $26,000. Clarity Asset Management Inc. bought a new stake in Pfizer in the 4th quarter valued at $27,000. Gould Capital LLC boosted its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer in the 4th quarter valued at $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer in the 4th quarter valued at $30,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Up 2.6%

Shares of NYSE PFE opened at $23.97 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The firm’s 50-day moving average is $22.93 and its 200-day moving average is $24.98. The firm has a market capitalization of $136.26 billion, a PE ratio of 17.00, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period last year, the company earned $0.82 earnings per share. The firm’s revenue was down 7.8% compared to the same quarter last year. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.18%. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective for the company. Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.